Influence of charge on cell permeability and tumor imaging of GPR30-targeted 111In-labeled nonsteroidal imaging agents

ACS Chemical Biology

Volumn 5, Issue 7, 2010, Pages 681-690

  Nayak, Tapan K ^a,b   Dennis, Megan K ^a   Ramesh, Chinnasamy ^d   Burai, Ritwik ^d   Atcher, Robert W ^b,c,e   Sklar, Larry A ^a,b,c   Norenberg, Jeffrey P ^a,b   Hathaway, Helen J ^a   Arterburn, Jeffrey B ^c,d   Prossnitz, Eric R ^a,c  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d NEW MEXICO STATE UNIVERSITY   (United States)

^e LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATE; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; INDIUM 111; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM MOBILIZATION; CANCER DIAGNOSIS; CELL MEMBRANE PERMEABILITY; CELL SURFACE; CONTROLLED STUDY; ELECTRICITY; ENDOMETRIUM CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ANIMALS; BINDING, COMPETITIVE; BREAST NEOPLASMS; ELECTRIC CONDUCTIVITY; ENDOMETRIAL NEOPLASMS; ENZYME ACTIVATION; ESTROGENS; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MICE; MICE, KNOCKOUT; OVARIAN NEOPLASMS; PERMEABILITY; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; TISSUE DISTRIBUTION; UTERINE NEOPLASMS;

MUS;

EID: 77955014125     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb1000636     Document Type: Article

References (33)

1. Nilsson, S., Makela, S., Treuter, E., Tujague, M., Thomsen, J., Andersson, G., Enmark, E., Pettersson, K., Warner, M., and Gustafsson J. A. (2001) Mechanisms of estrogen action, Physiol. Rev. 81, 1535-1565.
2. Filardo, E. J., Quinn, J. A., Bland, K. I., and Frackelton, A. R. Jr. (2000) Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF, Mol. Endocrinol. 14,1649-1660.
3. Revankar, C. M., Cimino, D. F., Sklar, L A., Arterburn, J. B., and Prossnitz, E. R. (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling, Science 307,1625-1630.
4. Thomas, P., Pang, Y., Filardo, E.J., and Dong, J. (2005) Identityofan estrogen membrane receptor coupled to a G protein in human breast cancer cells, Endocrinology 146, 624-632.
5. Revankar, C. M., Mitchell, H. D., Field, A. S., Burai, R., Corona, C., Ramesh, C., Sklar, L A., Arterburn, J. B., and Prossnitz, E. R. (2007) Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30, ACS Chem. Biol. 2, 536-544.
6. Filardo, E., Quinn, J., Pang, Y., Graeber, C., Shaw, S., Dong, J., and Thomas, P. (2007) Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane, Endocrinology 148, 3236-3245.
7. Bologa, C. G., Revankar, C. M., Young, S. M., Edwards, B. S., Arterburn, J. B., Kiselyov, A. S., Parker, M. A., Tkachenko, S. E., Savchuck, N. P., Sklar, L A., Oprea, T. I., and Prossnitz, E. R. (2006) Virtual and biomolecular screening converge on a selective agonist for GPR30, Nat. Chem. Biol. 2, 207-212.
8. Dennis, M. K., Burai, R., Ramesh, C., Petrie, W. K., Alcon, S. N., Nayak, T. K., Bologa, C. G., Leitao, A., Brailoiu, E., Deliu, E., Dun, N. J., Sklar, L A., Hathaway, H. J., Arterburn, J. B., Oprea, T. I., and Prossnitz, E. R. (2009) In vivo effects of a GPR30 antagonist, Nat. Chem. Biol. 5, 421-427.
9. Blasko, E., Haskell, C. A., Leung, S., Gualtieri, G., Halks-Miller, M., Mahmoudi, M., Dennis, M. K., Prossnitz, E. R., Karpus, W. J., and Horuk, R. (2009) Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis, J. Neuroimmunol. 214, 67-77.
10. Xu, H., Qin, S., Carrasco, G. A., Dai, Y., Filardo, E. J., Prossnitz, E. R., Battaglia, G., Doncarlos, L L., and Muma, N. A. (2009) Extranuclear estrogen receptor GPR30 regulates serotonin function in rat hypothalamus, Neuroscience 158,1599-1607.
11. Haas, E., Bhattacharya, I., Brailoiu, E., Damjanovic, M., Brailoiu, G. C., Gao, X., Mueller-Guerre, L., Marjon, N. A., Gut, A., Minotti, R., Meyer, M. R., Amann, K., Ammann, E., Perez-Dominguez, A., Genoni, M., Clegg, D.J., Dun, N.J., Resta, T. C., Prossnitz, E. R., and Barton, M. (2009) Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity, Circ. Res. 104, 288-291.
12. Teng, J., Wang, Z. Y., Prossnitz, E. R., and Bjorling, D. E. (2008) The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation, Endocrinology 149,4024-4034.
13. Olde, B., and Leeb-Lundberg, L M. (2009) GPR30/GPER1: searching for a role in estrogen physiology, Trends Endocrinol. Metab. 20, 409-416.
14. Martensson, U. E., Salehi, S.A., Windahl, S., Gomez, M. F., Sward, K., Daszkiewicz-Nilsson, J., Wendt, A., Andersson, N., Hellstrand, P., Grande, P. O., Owman, C., Rosen, C. J., Adamo, M. L., Lundquist, I., Rorsman, P., Nilsson, B. O., Ohlsson, C., Olde, B., and Leeb-Lundberg, L. M. (2009) Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice, Endocrinology 150, 687-698.
15. Filardo, E.J., Graeber, C.T., Quinn, J. A., Resnick, M. B., Giri, D., DeLellis, R. A., Steinhoff, M. M., and Sabo, E. (2006) Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression, Clin. Cancer Res. 12, 6359-6366.
16. Smith, H. O., Leslie, K. K., Singh, M., Qualls, C. R., Revankar, C. M., Joste, N. E., and Prossnitz, E. R. (2007) GPR30: a novel indicator of poor survival for endometrial carcinoma, Am. J. Obstet. Gynecol. 196, e381-389; discussion e389-311.
17. Smith, H. O., Arias-Pulido, H., Kuo, D. Y., Howard, T., Qualls, C. R., Lee, S. J., Verschraegen, C. F., Hathaway, H. J., Joste, N. E., and Prossnitz, E. R. (2009) GPR30 predicts poor survival for ovarian cancer, Gynecol. Oncol. 114,465-471.
18. Mortimer, J. E., Dehdashti, F., Siegel, B. A., Katzenellenbogen, J. A., Fracasso, P., and Welch, M.J. (1996) Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose and 16α-[18F]fluoro-17β-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy, Clin. Cancer Res. 2, 933-939.
19. Tsujikawa, T., Yoshida, Y., Mori, T., Kurokawa, T., Fujibayashi, Y., Kotsuji, F., and Okazawa, H. (2008) Uterine tumors: pathophysiologic imagingwith 16α-[18F]fluoro-17β-estradioland 18Ffluorodeoxyglu-cose PET - initial experience, Radiology 248, 599-605.
20. Yoshida, Y., Kurokawa, T., Tsujikawa, T., Okazawa, H., and Kotsuji, F. (2009) Positron emission tomography in ovarian cancer: 18F-deoxy-glucose and 16α-18F-fluoro-17β-estradiol PET, J. Ovarian Res. 2, 7.
21. Yoshida, Y., Kurokawa, T., Sawamura, Y., Shinagawa, A., Okazawa, H., Fujibayashi, Y., and Kotsuji, F. (2007) The positron emission tomography with F18 17β-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer, Gynecol. Oncol. 104, 764-766.
22. Linden, H. M., Stekhova, S.A., Link, J. M., Gralow, J. R., Livingston, R. B., Ellis, G. K., Petra, P. H., Peterson, L. M., Schubert, E. K., Dunnwald, L. K., Krohn, K. A., and Mankoff, D. A. (2006) Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer, J. Clin. Oncol. 24, 2793-2799.
23. Dehdashti, F., Mortimer, J. E., Trinkaus, K., Naughton, M. J., Ellis, M., Katzenellenbogen, J. A., Welch, M. J., and Siegel, B. A. (2009) PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer, Breast Cancer Res. Treat. 113,509-517.
24. Ramesh, C., Nayak, T. K., Burai, R., Dennis, M. K., Hathaway, H. J., Sklar, L. A., Prossnitz, E. R., and Arterburn J. B. (2010) Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30, J. Med. Chem. 53, 1004-1014.
25. Lashley, M. R., Niedzinski, E. J., Rogers, J. M., Denison, M. S., and Nantz, M. H. (2002) Synthesis and estrogen receptor affinity of a 4-hydroxytamoxifen-labeled ligand for diagnostic imaging, Bioorg. Med. Chem. 10,4075-4082.
26. Banerjee, S., Das, T., Chakraborty, S., Samuel, G., Korde, A., Venkatesh, M., and Pillai, M. R. (2005) An estradiol-conjugate for radio-labelling with 177Lu: an attempt to prepare a radiotherapeutic agent Bioorg. Med. Chem. 13,4315-4322.
27. Delpassand, E. S., Yang, D. J., Wallace, S., Cherif, A., Quadri, S. M., Price, J., Joubert, A., Inoue, T., and Podoloff, D. A. (1996) Synthesis, biodistribution, and estrogen receptorscintigraphy of indium-111- diethylenetriaminepentaacetic acid-tamoxifen analogue, J. Pharm. Sci. 85, 553-559.
28. Gunanathan, C., Pais, A., Furman-Haran, E., Seger, D., Eyal, E., Mukhopadhyay, S., Ben-David, Y., Leitus, G., Cohen, H., Vilan, A., Degani, H., and Milstein, D. (2007) Water-soluble contrast agents targeted at the estrogen receptor for molecular magnetic resonance imaging, Bioconjugate Chem. 18,1361-1365.
29. Lewis, M. R., Raubitschek, A., and Shively, J. E. (1994) A facile, watersoluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates, Bioconjugate Chem. 5, 565-576.
30. Deshpande, S. V., DeNardo, S. J., Kukis, D. L., Moi, M. K., McCall, M. J., DeNardo, G. L., and Meares, C. F. (1990) Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctionalchelating agent, J. Nucl. Med. 31, 473-479.
31. Wu, S. L., Johnson, K. A., and Horrocks, W. D., Jr. (1997) Kinetics of formation of Ca(2+) complexes of acyclic and macrocyclic poly-(amino carboxylate) ligands: bimolecular rate constants forthefullydeprotonated ligands reveal the effect of macrocyclic ligand constraints on the rate-determining conversions of rapidly-formed intermediates to the final complexes, Inorg. Chem. 36, 1884-1889.
32. Ramesh, C., Bryant, B., Nayak, T., Revankar, CM., Anderson, T., Carlson, K. E., Katzenellenbogen, J. A., Sklar, L. A., Norenberg, J. P., Prossnitz, E. R., and Arterburn, J. B. (2006) Linkage effects on binding affinity and activation of GPR30 and estrogen receptors ERα/β with tridentate pyridin-2-yl hydrazine tricarbonyl-Re/(99m)Tc(I) chelates, J. Am. Chem. Soc. 128, 14476-14477.
33. Nayak, T. K., Hathaway, H. J., Ramesh, C., Arterburn, J. B., Dai, D., Sklar, L. A., Norenberg, J. P., and Prossnitz, E. R. (2008) Preclinical development of a neutral, estrogen receptor-targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers, J. Nucl. Med. 49, 978-986.